BOK Financial Private Wealth Inc. Has $896,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

BOK Financial Private Wealth Inc. cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 1.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 12,098 shares of the medical research company’s stock after selling 222 shares during the quarter. BOK Financial Private Wealth Inc.’s holdings in Edwards Lifesciences were worth $896,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Argentarii LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $256,000. OFI Invest Asset Management acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $22,705,000. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Edwards Lifesciences by 33.5% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 127,436 shares of the medical research company’s stock valued at $10,411,000 after purchasing an additional 31,972 shares during the last quarter. Aviance Capital Partners LLC raised its holdings in shares of Edwards Lifesciences by 8.3% in the fourth quarter. Aviance Capital Partners LLC now owns 7,794 shares of the medical research company’s stock valued at $577,000 after purchasing an additional 600 shares during the last quarter. Finally, Destination Wealth Management raised its holdings in shares of Edwards Lifesciences by 12.6% in the fourth quarter. Destination Wealth Management now owns 7,893 shares of the medical research company’s stock valued at $584,000 after purchasing an additional 881 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $70.78, for a total transaction of $796,275.00. Following the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,150,791.86. The trade was a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,739 shares of company stock worth $2,799,104 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 2.0 %

EW stock opened at $70.36 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company’s 50-day simple moving average is $72.26 and its 200 day simple moving average is $70.38. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market capitalization of $41.37 billion, a PE ratio of 10.10, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

EW has been the topic of a number of recent analyst reports. Citigroup boosted their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Truist Financial restated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.